PEGylation is a process of addition of active polyethylene glycol (PEG) to different forms of therapeutic proteins for chemical modification. These chemically modified therapeutic proteins are called PEGylated protein therapeutics. PEGylated protein therapeutics are used in multiple conditions, such as cancer, hemophilia, rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, and others. PEGylation is the term used to describe the covalent modification of biological molecules with the non-toxic, non-immunogenic polymer polyethylene glycol (PEG) in order to reduce the drawbacks of some biopharmaceuticals.

Due to its claimed "silent" qualities and biocompatibility, polyethylene glycol (PEG) is frequently used in medication delivery and nanotechnology. It is commonly accepted that PEGylation enables biomaterials and particle delivery methods to sidestep the immune system and extend circulation lifetimes. Nevertheless, PEGylation of proteins is a complicated procedure that can be completed using a variety of methods, depending on the type of the protein and the intended application. Inert PEG strings are covalently or non-covalently complexed with proteins of interest. Another crucial step is the purification of the PEGylated protein, which is mostly accomplished through chromatography and electrostatic interactions or molecular sizes.

Market Dynamics

Increasing adoption of inorganic strategies by key players in market such as product launch is expected to drive market growth over the forecast period. For instance, in February 2020, the Novo Nordisk launched ESPEROCT in the U.S. for the treatment of people with hemophilia A. It is a recombinant extended half-life factor VIII replacement therapy used to prevent or reduce the number of bleeding episodes, to treat and control bleeding, and to manage bleeding during surgery in people with hemophilia A. ESPEROCT is antihemophilic factor (recombinant), glycopegylated-exei. 

Key features of the study:

• This report provides an in-depth analysis of the global PEGylated proteins market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global PEGylated proteins market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Biogen Inc, Pfizer Inc, UCB S.A., Leadiant Biosciences, Inc., Amgen Inc., Thermo Fisher Scientific Inc., Horizon Therapeutics Plc., Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bayer AG, BioMarin, RedHill Biopharma Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global PEGylated proteins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PEGylated proteins market

Detailed Segmentation:

• Global PEGylated Proteins Market, By Type:
  • Consumables
  • Services
• Global PEGylated Proteins Market, By Protein:
  • Colony-stimulating factor
  • Interferons
  • Erythropoietin
  • Recombinant factor VII
  • Other
• Global PEGylated Proteins Market, By Application:
  • Cancer
  • Autoimmune Disease
  • Hepatitis
  • Multiple Sclerosis
  • Hemophilia
  • Gastrointestinal Disorder
  • Others
• Global PEGylated Proteins Market, By End User:
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Academic Research Institutes
• Global PEGylated Proteins Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Region/Country
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Biogen Inc, Pfizer Inc
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Pfizer Inc
  • UCB S.A.
  • Leadiant Biosciences, Inc.,
  • Amgen Inc.
  • Thermo Fisher Scientific Inc.
  • Horizon Therapeutics Plc.
  • Novo Nordisk A/S
  • Hoffmann-La Roche AG
  • Bayer AG
  • BioMarin
  • RedHill Biopharma Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.